Lack of adipose tissue results in marked hypoleptinemia in patients with lipodystrophy. These patients have an increased risk of difficult to treat metabolic disorders including hypertriglyceridemia, marked insulin resistance, type 2 diabetes, recurrent pancreatitis, fatty liver disease, NASH, and liver fibrosis

Various trials have been carried out to study the efficacy of Human recombinant leptin (metreleptin) in patients with lipodystrophy.

A 2011 study by Chan et al